SGN 624
Alternative Names: SGN-624Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator SGN Nanopharma
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Postoperative pain
Most Recent Events
- 31 Dec 2024 Preclinical trials in Pain in USA (Transdermal) before December 2024 (SGN Nanopharma pipeline, December 2024)